T1	Intervention 10 19	aliskiren
T2	Intervention 23 34	proteinuria
T3	Intervention 38 73	non-diabetic chronic kidney disease
T4	Intervention 77 112	double-blind, crossover, randomised
T5	Intervention 186 201	renin inhibitor
T6	Intervention 227 234	placebo
T7	Intervention 245 284	angiotensin-converting enzyme inhibitor
T8	Intervention 317 352	non-diabetic chronic kidney disease
T9	Intervention 426 474	patients with nondiabetic chronic kidney disease
T10	Intervention 480 501	24-h mean proteinuria
T11	Intervention 546 556	creatinine
T12	Intervention 608 630	five treatment periods
T13	Intervention 636 667	patients were randomly assigned
T14	Intervention 679 688	aliskiren
T15	Intervention 699 708	aliskiren
T16	Intervention 719 730	perindopril
T17	Intervention 739 750	perindopril
T18	Intervention 762 769	placebo
T19	Intervention 779 803	Aliskiren and perindopri
T20	Intervention 813 824	proteinuria
T21	Intervention 845 859	dose-dependent
T22	Intervention 874 890	24-h proteinuria
T23	Intervention 948 957	aliskiren
T24	Intervention 1054 1065	perindopril
T25	Intervention 1113 1124	perindopril
T26	Intervention 1146 1153	placebo
T27	Intervention 1203 1239	effects of aliskiren and perindopril
T28	Intervention 1253 1262	Aliskiren
T29	Intervention 1285 1296	proteinuria
T30	Intervention 1302 1317	antiproteinuric
T31	Intervention 1356 1367	perindopril
T32	Intervention 1384 1403	hypotensive dosages
T33	Intervention 1409 1423	renin inhibito
T34	Intervention 1475 1496	treatment of patients
T35	Intervention 1510 1521	proteinuric
